Know Cancer

or
forgot password

A Randomized, Open-Label, Dose-Timing Study of Darbepoetin Alfa Administered Once Every 3 Weeks (Q3W) by Subcutaneous (SC) Injection for Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy


Phase 2
18 Years
N/A
Not Enrolling
Both
Lymphoma, Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Chronic Lymphocytic Leukemia

Thank you

Trial Information

A Randomized, Open-Label, Dose-Timing Study of Darbepoetin Alfa Administered Once Every 3 Weeks (Q3W) by Subcutaneous (SC) Injection for Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy

Inclusion Criteria


- Patients with non-myeloid malignancies * Patients receiving at least 12 weeks of
chemotherapy on a 3-week cycle schedule * Patients with anemia (hgb >/= 9.0 and 11.0 g/dL)

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

MD

Investigator Role:

Study Director

Investigator Affiliation:

Amgen

Authority:

United States: Food and Drug Administration

Study ID:

20010162

NCT ID:

NCT00036023

Start Date:

Completion Date:

Related Keywords:

  • Lymphoma
  • Breast Neoplasms
  • Lung Neoplasms
  • Multiple Myeloma
  • Chronic Lymphocytic Leukemia
  • Breast Neoplasms
  • Neoplasms
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Lung Neoplasms
  • Lymphoma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location